- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 11 Feb 2025
- Managers listing it
- 32
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 23 listed it in both
- Shares listed
- 246,173,170
- combined, among listed positions
- Reported value
- $11.0bn
- combined, at the quarter end
Among the 94 comparable managers: 17 buyers (opened or added shares) and 16 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing CVS in Q4 2024
32 of 32 holders
Largest increases and reductions, by shares
Increases
- Capital World Investorsexisting position · 61,039,777 shares now+12,819,148
- Dodge & Coxexisting position · 70,105,899 shares now+7,075,209
- Invesco Ltdexisting position · 18,038,089 shares now+4,173,243
- Holocene Advisors LPnew position · 2,635,862 shares now+2,635,862
- T. Rowe Price Associates Incexisting position · 13,366,403 shares now+1,660,321
Reductions
- Capital Research Global Investorsexisting position · 2,505,406 shares now-3,138,879
- Sachem Head Capital Management LPexisting position · 625,000 shares now-2,895,000
- Two Sigma Investments LPexisting position · 1,709,465 shares now-1,511,920
- AQR Capital Management LLCexisting position · 2,667,174 shares now-1,386,324
- Two Sigma Advisers LPexisting position · 836,100 shares now-1,264,600
New positions and exits
New (4)
Exited (3)
- Third Point LLCwas $99m
- Renaissance Technologies LLCwas $61m
- Caxton Associates LLPwas $617k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 19 | $12.0bn | n.a. | n.a. |
| Q3 2013 | 22 | $11.8bn | n.a. | n.a. |
| Q4 2013 | 19 | $14.0bn | n.a. | n.a. |
| Q1 2014 | 17 | $15.3bn | n.a. | n.a. |
| Q2 2014 | 24 | $14.7bn | n.a. | n.a. |
| Q3 2014 | 21 | $15.4bn | n.a. | n.a. |
| Q4 2014 | 24 | $18.3bn | n.a. | n.a. |
| Q1 2015 | 25 | $19.7bn | n.a. | n.a. |
| Q2 2015 | 24 | $20.2bn | n.a. | n.a. |
| Q3 2015 | 30 | $19.0bn | n.a. | n.a. |
| Q4 2015 | 25 | $17.8bn | n.a. | n.a. |
| Q1 2016 | 24 | $17.1bn | n.a. | n.a. |
| Q2 2016 | 34 | $14.3bn | n.a. | n.a. |
| Q3 2016 | 30 | $12.8bn | n.a. | n.a. |
| Q4 2016 | 32 | $9.3bn | n.a. | n.a. |
| Q1 2017 | 29 | $8.7bn | n.a. | n.a. |
| Q2 2017 | 20 | $9.0bn | n.a. | n.a. |
| Q3 2017 | 23 | $9.4bn | n.a. | n.a. |
| Q4 2017 | 32 | $10.5bn | n.a. | n.a. |
| Q1 2018 | 31 | $8.7bn | n.a. | n.a. |
| Q2 2018 | 21 | $8.1bn | n.a. | n.a. |
| Q3 2018 | 25 | $10.7bn | n.a. | n.a. |
| Q4 2018 | 33 | $11.4bn | n.a. | n.a. |
| Q1 2019 | 27 | $8.5bn | n.a. | n.a. |
| Q2 2019 | 25 | $8.0bn | n.a. | n.a. |
| Q3 2019 | 25 | $9.6bn | n.a. | n.a. |
| Q4 2019 | 27 | $11.4bn | n.a. | n.a. |
| Q1 2020 | 29 | $8.1bn | n.a. | n.a. |
| Q2 2020 | 26 | $9.3bn | n.a. | n.a. |
| Q3 2020 | 29 | $8.9bn | n.a. | n.a. |
| Q4 2020 | 22 | $9.8bn | n.a. | n.a. |
| Q1 2021 | 28 | $10.3bn | n.a. | n.a. |
| Q2 2021 | 24 | $11.8bn | n.a. | n.a. |
| Q3 2021 | 28 | $11.9bn | n.a. | n.a. |
| Q4 2021 | 28 | $14.7bn | n.a. | n.a. |
| Q1 2022 | 25 | $14.4bn | n.a. | n.a. |
| Q2 2022 | 30 | $13.5bn | n.a. | n.a. |
| Q3 2022 | 28 | $13.9bn | n.a. | n.a. |
| Q4 2022 | 30 | $12.6bn | n.a. | n.a. |
| Q1 2023 | 36 | $9.6bn | n.a. | n.a. |
| Q2 2023 | 33 | $9.8bn | n.a. | n.a. |
| Q3 2023 | 33 | $11.7bn | n.a. | n.a. |
| Q4 2023 | 32 | $14.2bn | 15 | 18 |
| Q1 2024 | 21 | $14.3bn | 9 | 14 |
| Q2 2024 | 24 | $14.2bn | 16 | 8 |
| Q3 2024 | 31 | $14.2bn | 23 | 10 |
| Q4 2024 | 32 | $11.0bn | 17 | 16 |
| Q1 2025 | 29 | $19.1bn | 20 | 10 |
| Q2 2025 | 31 | $19.6bn | 19 | 12 |
| Q3 2025 | 28 | $21.9bn | 16 | 11 |
| Q4 2025 | 29 | $22.8bn | 18 | 23 |
| Q1 2026 | 32 | $21.1bn | 24 | 20 |
| Q2 2026 | 31 | $30.8bn | 18 | 24 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CVS and PM →CVS and KO →CVS and COST →Choose a stock to compare with CVS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CVS, latest filings →Back to the 13F Explorer →